TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18427723
Drug: Tacrolimus (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus (oral, ≤3 mg once daily for 76 weeks)
Study: 18427723
Drug: Mizoribine (previous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizoribine (previous treatment)
Study: 22089267
Drug: High-dose ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ibuprofen (20-10-10 mg/kg/day)
Study: 22089267
Drug: Standard-dose ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose ibuprofen (10-5-5 mg/kg/day)
Study: 9648050
Drug: NNC 01-0687
Normalized name: NNC-55-0396 free base
DrugBank: NNC-55-0396 free base (DB17037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC 01-0687 (dopamine D1 antagonist)
Study: 824215
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam (DZ)
Study: 29227351
Drug: PECS block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: PECS block with 30 ml of levobupivacaine 0.25% after induction of anaesthesia
Study: 20545689
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement (DS) containing Lactobacillus johnsonii (La1) and carotenoids for 10 weeks
Study: 9974369
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) - nadroparin, 85 anti-Xa IU/kg s.c. once daily
Study: 9974369
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant (OA) - acenocoumarol
Study: 7673609
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg once daily for 4 weeks, followed by famotidine 20 mg twice daily for 4 weeks
Study: 7673609
Drug: Famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 20 mg twice daily for 4 weeks, followed by lansoprazole 30 mg once daily for 4 weeks
Study: 2206878
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVGG) 800 mg/kg
Study: 2206878
Drug: Intravenous albumin
Normalized name: albumin human, USP Injection [Albuminar]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous albumin
Study: 7193003
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation A (Acetylsalicylic acid + glycine)
Study: 7193003
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation B (Microencapsulated Acetylsalicylic acid)
Study: 7193003
Drug: Both ASA
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both ASA preparations (1000 mg ASA)
Study: 7193003
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation A
Study: 7193003
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation B
Study: 28789492
Drug: linagliptin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin (5 mg/d)
Study: 25808394
Drug: Pregabalin CR
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin CR 330 mg alone
Study: 25808394
Drug: Pregabalin CR
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin CR 330 mg co-administered with erythromycin 500 mg
Study: 12639353
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 1 mg/kg IM
Study: 12639353
Drug: Tramadol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 1.5 mg/kg IM
Study: 12639353
Drug: Eutectic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eutectic mixture local anesthetic (EMLA) cream 15 g
Study: 10674777
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (risperidone, olanzapine)
Study: 3889748
Drug: Aztreonam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam (2 g intravenously every eight hours) with clindamycin (600 mg intravenously every six hours)
Study: 3889748
Drug: Gentamicin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (1.5 mg/kg intravenously every eight hours) with clindamycin (600 mg intravenously every six hours)
Study: 3889748
Drug: Clindamycin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (600 mg intravenously every six hours)
Study: 23053638
Drug: EC‐D (epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC‐D (epirubicin 90 mg/m(2) plus cyclophosphamide 600 mg/m(2) for 4 cycles followed by docetaxel 100 mg/m(2) × 4 cycles)
Study: 23053638
Drug: EC‐DCb (epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC‐DCb (epirubicin 90 mg/m(2) plus cyclophosphamide 600 mg/m(2) for 4 cycles followed by docetaxel 75 mg/m(2) plus carboplatin AUC 6 × 4 cycles)
Study: 18589560
Drug: Memantine 10
Normalized name: Memantine 10mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine 10 mg
Study: 2652084
Drug: Spiramycin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiramycin (100 mg/kg/day for 10 days)
Study: 582709
Drug: Domperidone 50
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 50 mg
Study: 22646975
Drug: Waiting-list control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting-list control group (no treatment)
Study: 17982722
Drug: Fosfomycin (FOM)
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin (FOM) 2 g/dose, drip infused starting 30 min before surgery and twice daily for 3 days after surgery
Study: 17982722
Drug: Cefotiam (CTM)
Normalized name: cefotiam
DrugBank: Cefotiam (DB00229)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefotiam (CTM) 1 g/dose, drip infused starting 30 min before surgery and twice daily for 3 days after surgery
Study: 15342674
Drug: CETP inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: CETP inhibitors
Study: 11229617
Drug: delta9-THC (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: delta9-THC (5.0 to 10.0 mg)
Study: 7736528
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies against CA125
Study: 7736528
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies against TAG72
Study: 2758104
Drug: Arbaprostil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arbaprostil (50 micrograms) and Aspirin (975 mg) coadministration
Study: 2758104
Drug: Aspirin (975
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (975 mg) alone
Study: 2758104
Drug: Salicylate pharmacokinetics
Normalized name: salicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salicylate pharmacokinetics
Study: 676309
Drug: Daily administration
Normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of 1200 IU vitamin D3
Study: 30670010
Drug: Amla extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amla extract (500 mg) administered twice daily for 12 weeks
Study: 27193080
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl (1.5 mcg/kg) + intravenous tramadol (2 mg/kg)
Study: 25311995
Drug: Ivacaftor 150
Normalized name: ivacaftor 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivacaftor 150 mg every 12 hours
Study: 15354916
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL of 0.5% bupivacaine with 1:200,000 epinephrine and 1 microg/kg of clonidine
Study: 15354916
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL of 0.5% bupivacaine with 1:200,000 epinephrine (control group)
Study: 8210255
Drug: CPT-11 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT-11 (100 mg/m2 weekly intravenous infusion, regimen A)
Study: 8210255
Drug: CPT-11 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPT-11 (150 mg/m2 every two weeks, regimen B)
Study: 802630
Drug: Diuretic plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic plus methyldopa
Study: 29065278
Drug: 3 mg·kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg·kg‐1 body mass caffeine
Study: 29065278
Drug: 6 mg·kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg·kg‐1 body mass caffeine
Study: 26694130
Drug: G-CSF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (5 μg/kg/d Lenograstim from day 2 after each course of six chemotherapy courses)
Study: 26694130
Drug: G-CSF- (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF- (no G-CSF administration)
Study: 21773849
Drug: Hospital Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital Medicine Physician Worklife Survey
Study: 18349272
Drug: Supplemental alpha-tocopherol
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental alpha-tocopherol (50 mg/d) and/or beta-carotene (20 mg/d)
Study: 1281650
Drug: Initial chemotherapy
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial chemotherapy with sequential methotrexate‐5‐FU with leucovorin rescue (MFL) for 6 months
Study: 1281650
Drug: Primary expectancy
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary expectancy with chemotherapy only after the appearance of symptoms
Study: 31027883
Drug: Sevelamer (1,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevelamer (1,600 mg thrice daily) for 3 months
Study: 31027883
Drug: Sevelamer treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevelamer treatment
Study: 24671450
Drug: TAK-442 (pooled
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-442 (pooled doses)
Study: 24671450
Drug: TAK-442 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-442 (various doses)
Study: 21809603
Drug: Injectable lidocaine
Normalized name: lidocaine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable lidocaine 2% solution (1.5 ml)
Study: 21809603
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine 2% gel (1.5 ml)
Study: 18413426
Drug: 2,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,000 IU oral vitamin D2 daily
Study: 18413426
Drug: 50,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50,000 IU vitamin D2 weekly
Study: 18413426
Drug: 2,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,000 IU vitamin D3 daily
Study: 11831538
Drug: ERA-923 (10-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERA-923 (10-200 mg)
Study: 1682643
Drug: monocomponent pertussis
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: monocomponent pertussis toxoid vaccine
Study: 1682643
Drug: two-component acellular
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: two-component acellular vaccine also containing filamentous haemagglutinin
Study: 1682643
Drug: 20% albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% albumin solution (placebo)
Study: 6756799
Drug: Oxipor VHC
Normalized name: Oxipor VHC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxipor VHC lotion
Study: 6756799
Drug: Tegrin lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegrin lotion
Study: 24351402
Drug: 10% urea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% urea cream (arm B)
Study: 17476705
Drug: Tiagabine 4-16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine 4-16 mg per day for 12 weeks
Study: 15148924
Drug: Levofloxacin, Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin, Chinese traditional medicine and microwave
Study: 9536926
Drug: NG‐monomethyl L‐arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG‐monomethyl L‐arginine (3 mg h‐1 kg‐1)
Study: 1990984
Drug: Generic topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic topical steroids
Study: 1990984
Drug: Trade-name topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trade-name topical steroids
Study: 6337004
Drug: Epoprostenol (PGI2)
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoprostenol (PGI2) infusion at doses of 2, 4, 6, and 8 ng/kg/min
Study: 6337004
Drug: Dipyridamole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (400 mg/day for 3 days)
Study: 24893962
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg of sublingual misoprostol
Study: 31926328
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive treatment (endoscopic approach)
Study: 31926328
Drug: Conventional Bascom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Bascom cleft lift treatment
Study: 31926328
Drug: Cost analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost analysis of minimally invasive treatment
Study: 24190860
Drug: High-dose n-3
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose n-3 PUFA (Lovaza 3600 mg/day)
Study: 24190860
Drug: Low-dose n-3
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose n-3 PUFA (Lovaza 900 mg/day)
Study: 17337426
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate 100 mg oral treatment
Study: 15778966
Drug: Three-dose hepatitis
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose hepatitis B vaccination course (Engerix B GlaxoSmithKline) administered at 0, 1, and 12 months; adult dose containing 20 mug recombinant hepatitis B surface antigen in 1 ml suspension.
Study: 9295239
Drug: Isoniazid daily
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid daily for six months
Study: 9295239
Drug: Isoniazid and
Normalized name: Isoniazid and rifampin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid and rifampin daily for three months
Study: 9295239
Drug: Isoniazid, rifampin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid, rifampin, and pyrazinamide daily for three months
Study: 7509573
Drug: Structured sensorimotor
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured sensorimotor therapy
Study: 3539030
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms intranasal DDAVP
Study: 30149145
Drug: SGLT2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitors (dapagliflozin)
Study: 20236776
Drug: Vaginal oestradiol
Normalized name: estradiol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal oestradiol (25 micrograms, Vagifem, Novo Nordisk) once daily for 2 weeks, then twice weekly for 6 months (group 1)
Study: 12872170
Drug: Thiopental, nitrous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental, nitrous oxide, and low-dose isoflurane
Study: 8927680
Drug: Zotepine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zotepine (150 to 300 mg)
Study: 8927680
Drug: Haloperidol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (10 to 20 mg)
Study: 1294919
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl 70-80 micrograms/hr
Study: 1294919
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl 90-100 micrograms/hr
Study: 1294919
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine 150 micrograms/kg every 6h
Study: 6364994
Drug: 1% sulconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% sulconazole cream
Study: 6364994
Drug: 2% miconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% miconazole cream
Study: 18035195
Drug: Ibutilide 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide 0.01 mg/kg
Study: 18035195
Drug: Ibutilide 0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide 0.02 mg/kg
Study: 18035195
Drug: Ibutilide 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide 0.5 mg
Study: 18035195
Drug: Ibutilide 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide 0.75 mg
Study: 18035195
Drug: Ibutilide 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide 1.0 mg
Study: 12042266
Drug: Trilostane 1080
Normalized name: TRILOSTANE
DrugBank: Trilostane (DB01108)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trilostane 1080 mg
Study: 12042266
Drug: Trilostane 720
Normalized name: TRILOSTANE
DrugBank: Trilostane (DB01108)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trilostane 720 mg
Study: 10214664
Drug: New corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: New corticosteroid drug
Study: 7833731
Drug: Metformin (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (in obese subjects)
Study: 2226910
Drug: Norethindrone 1
Normalized name: norethindrone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethindrone 1 mg/mestranol 0.05 mg/d (group A)
Study: 31159548
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy with automated instillation
Study: 31159548
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard negative pressure therapy)
Study: 27513627
Drug: iPad administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iPad administration of ICIQ questionnaires
Study: 27513627
Drug: Telephone administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telephone administration of ICIQ questionnaires
Study: 27513627
Drug: Paper administration
Normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper administration of ICIQ questionnaires
Study: 25533601
Drug: Progressive resistance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive resistance exercise program (3 sets of 10 to 12 leg extensions at 70% of estimated 1-repetition maximum thrice weekly for 8 weeks)
Study: 20078697
Drug: One-step self-etch
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-step self-etch bonding agent
Study: 20078697
Drug: Two-step total-etch
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two-step total-etch bonding agent
Study: 15672116
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium and normal protein (HC/NP: 1800 mg calcium, 15% of energy from protein)
Study: 15672116
Drug: Low calcium
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calcium and normal protein (LC/NP: 500 mg calcium, 15% of energy from protein)
Study: 15672116
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium and high protein (HC/HP: 1800 mg calcium, 23% of energy from protein)
Study: 8708586
Drug: Intensive advice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive advice (no drug)
Study: 8708586
Drug: Usual advice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual advice (no drug)
Study: 6813126
Drug: NTG-TTS (transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTG-TTS (transdermal therapeutic system for nitroglycerin)
Study: 19110786
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg clopidogrel maintenance dose
Study: 19110786
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg clopidogrel maintenance dose (control)
Study: 17130267
Drug: Nonatorvastatin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonatorvastatin therapy
Study: 12939009
Drug: Single-stage implants
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-stage implants with screw-retained restorations
Study: 12939009
Drug: Single-stage implants
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-stage implants with cemented restorations
Study: 12939009
Drug: Single-stage implants
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-stage implants in completely edentulous patients
Study: 12939009
Drug: Single-stage implants
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-stage implants in partially edentulous patients
Study: 11039684
Drug: Child‐focused cognitive‐behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child‐focused cognitive‐behaviour therapy (CBT)
Study: 6661342
Drug: Propranolol administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol administration during exercise
Study: 28990807
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioural therapy for tinnitus
Study: 20061838
Drug: Gabapentin in
Normalized name: Product containing gabapentin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin in combination therapy with two antihistamines
Study: 20061838
Drug: Chlorpheniramine in
Normalized name: chlorpheniramine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine in combination with two antihistamines
Study: 16984938
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (60 mg daily for the first week and 40 mg daily for the second week)
Study: 12944994
Drug: Adjuvant cytotoxic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant cytotoxic therapy
Study: 8949825
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of edrophonium 1 mg kg‐1 and exogenous PCHE equivalent to activity present in 25 ml kg‐1 of human plasma
Study: 8949825
Drug: Edrophonium 1
Normalized name: edrophonium 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 1 mg kg‐1 (group ED)